异源高剂量严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗加强针可能改善血清阴性肾移植受者的免疫反应。
Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients.
作者信息
Tylicki Leszek, Biedunkiewicz Bogdan, Ślizień Zuzanna, Muchlado Marta, Dębska-Ślizień Alicja
机构信息
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.
Medical students of the Medical University of Gdansk, Gdansk, Poland.
出版信息
Arch Med Sci. 2022 Jun 23;18(4):1100-1102. doi: 10.5114/aoms/150000. eCollection 2022.
Abstract
INTRODUCTION
Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects.
METHODS
The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative kidney transplant recipients (KTRs) after three doses of the BNT162b2 mRNA vaccine. Twelve seronegative KTRs received a mRNA-1273 booster 5 months after the third dose of BNT162b2.
RESULTS
A total of 5 out of 12 patients (41.7%) seroconverted, with a mean titer of 353 BAU/ml.
CONCLUSIONS
The administration of a heterologous mRNA vaccine as a booster may be an effective alternative for achieving post-vaccination immunity in seronegative KTRs.
摘要
引言
三剂新冠病毒mRNA疫苗接种方案无法在免疫功能低下的受试者中引发足够的免疫反应。
方法
本研究旨在对持续血清学阴性的肾移植受者（KTR）在接种三剂BNT162b2 mRNA疫苗后使用mRNA-1273进行异源mRNA加强免疫的疗效进行回顾性评估。12名血清学阴性的KTR在第三剂BNT162b2接种5个月后接受了mRNA-1273加强免疫。
结果
12名患者中有5名（41.7%）出现血清转化，平均滴度为353 BAU/ml。
结论
给予异源mRNA疫苗作为加强免疫可能是在血清学阴性的KTR中实现疫苗接种后免疫的有效替代方案。
相似文献
1
Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients.异源高剂量严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗加强针可能改善血清阴性肾移植受者的免疫反应。
Arch Med Sci. 2022 Jun 23;18(4):1100-1102. doi: 10.5114/aoms/150000. eCollection 2022.
2
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
3
Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.日本肾移植受者接种第二剂SARS-CoV-2 mRNA疫苗后的长期体液免疫反应
Front Microbiol. 2022 Jun 9;13:922042. doi: 10.3389/fmicb.2022.922042. eCollection 2022.
4
Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients.增强肾移植受者中mRNA新冠疫苗的体液免疫
Vaccines (Basel). 2021 Dec 31;10(1):56. doi: 10.3390/vaccines10010056.
5
The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.血液透析患者和肾移植受者对 BNT162b2 疫苗的体液免疫反应与循环 CD19+B 淋巴细胞和初始 CD45RA 至记忆 CD45RO CD4+T 辅助细胞比值相关。
Front Immunol. 2021 Dec 3;12:760249. doi: 10.3389/fimmu.2021.760249. eCollection 2021.
6
The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization.加强剂量mRNA疫苗对灭活或病毒载体疫苗免疫后的肾移植受者新冠病毒感染的影响
Vaccines (Basel). 2022 Oct 10;10(10):1690. doi: 10.3390/vaccines10101690.
7
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients-A Prospective Study.肾移植受者接种第三剂 BNT162b2 COVID-19 疫苗的免疫反应：一项前瞻性研究。
Transpl Int. 2022 Apr 21;35:10204. doi: 10.3389/ti.2022.10204. eCollection 2022.
8
Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.肾移植受者接受贝利尤单抗治疗后，对 3 剂 mRNA 疫苗的抗体反应较弱。
Am J Transplant. 2021 Dec;21(12):4043-4051. doi: 10.1111/ajt.16814. Epub 2021 Sep 12.
9
Benefits of Switching Mycophenolic Acid to Sirolimus on Serological Response after a SARS-CoV-2 Booster Dose among Kidney Transplant Recipients: A Pilot Study.肾移植受者在接受新冠病毒加强剂量疫苗后，将霉酚酸转换为西罗莫司对血清学反应的益处：一项试点研究
Vaccines (Basel). 2022 Oct 9;10(10):1685. doi: 10.3390/vaccines10101685.
10
Declined Humoral Immunity of Kidney Transplant Recipients to SARS-CoV-2 Vaccines.肾移植受者对SARS-CoV-2疫苗的体液免疫反应下降
Infect Drug Resist. 2023 May 9;16:2829-2840. doi: 10.2147/IDR.S408686. eCollection 2023.
引用本文的文献
1
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.实体器官移植受者对 SARS-CoV-2 感染的易感性和对 COVID-19 疫苗接种的免疫反应。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S34-S45. doi: 10.1093/infdis/jiad152.
2
Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.透析和肾移植患者接种 SARS-CoV-2 加强疫苗的疗效和安全性：系统评价和荟萃分析。
Int Urol Nephrol. 2023 Apr;55(4):791-802. doi: 10.1007/s11255-023-03471-x. Epub 2023 Feb 1.
本文引用的文献
1
Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第五剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后抗体反应改善：病例系列
Transplantation. 2022 May 1;106(5):e262-e263. doi: 10.1097/TP.0000000000004092. Epub 2022 Feb 15.
2
Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients.增强肾移植受者中mRNA新冠疫苗的体液免疫
Vaccines (Basel). 2021 Dec 31;10(1):56. doi: 10.3390/vaccines10010056.
3
REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme.再生元新冠病毒抗体组合疗法用于预防肾移植受者感染新冠病毒，这些受者对最佳疫苗接种方案无可检测到的抗体反应。
Kidney Int. 2022 Mar;101(3):645-646. doi: 10.1016/j.kint.2021.12.015. Epub 2022 Jan 4.
4
Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.对于一些人来说，用于新冠病毒暴露前预防的单克隆抗体来得不够快。
JAMA. 2021 Nov 16;326(19):1895-1897. doi: 10.1001/jama.2021.19534.
5
Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study-The COViNEPH Project.肾移植受者对mRNA新冠疫苗体液反应的预测因素：一项纵向研究——COViNEPH项目
Vaccines (Basel). 2021 Oct 12;9(10):1165. doi: 10.3390/vaccines9101165.
6
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
7
Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者第四剂 SARS-CoV-2 疫苗的抗体反应：病例系列。
Transplantation. 2021 Dec 1;105(12):e280-e281. doi: 10.1097/TP.0000000000003934.
8
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project.接受透析治疗患者接种 BNT162b2 mRNA COVID-19 疫苗的安全性和耐受性。COViNEPH 项目。
Medicina (Kaunas). 2021 Jul 19;57(7):732. doi: 10.3390/medicina57070732.
9
Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany.德国老年人对 BNT162b2 疫苗接种的迟发性抗体和 T 细胞反应。
Emerg Infect Dis. 2021 Aug;27(8):2174-2178. doi: 10.3201/eid2708.211145. Epub 2021 Jun 8.
10
COVID-19 and Solid Organ Transplantation: A Review Article.新型冠状病毒肺炎与实体器官移植：一篇综述文章。
Transplantation. 2021 Jan 1;105(1):37-55. doi: 10.1097/TP.0000000000003523.
Zotero 插件